8-K: Akoya Biosciences Reports Lower Than Expected Third Quarter Results Amidst Market Headwinds

Akoya Biosciences announced third quarter 2024 financial results that fell below expectations due to capital equipment purchase constraints in the life science tools market.

Summary

• Akoya Biosciences reported a 25% year-over-year decrease in revenue for the third quarter of 2024, totaling $18.8 million, compared to $25.2 million in the same period of 2023.
• The company's gross margin improved to 62.3% in Q3 2024, up from 60.6% in Q3 2023.
• Operating expenses decreased by 25% year-over-year to $20.1 million in Q3 2024.
• The loss from operations improved by 28% year-over-year to $8.3 million in Q3 2024.
• Akoya ended the third quarter with $39.3 million in cash, cash equivalents, and marketable securities.
• The installed base of instruments increased by 15% year-over-year to 1,299.
• The number of publications citing Akoya's technology increased by 47% year-over-year to 1,578.
• Year-to-date revenue for 2024 was $60.3 million, a 14% decrease compared to $70.1 million in the prior year period.
• Akoya has revised its full-year 2024 revenue outlook to a range of $80 million to $85 million, down from the previous range of $96 million to $104 million.
• The company is actively evaluating strategic alternatives to enhance growth and profitability.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the significant revenue decline and lowered guidance, despite some improvements in gross margin and operating expenses. The evaluation of strategic alternatives also introduces uncertainty.

Positives

• Gross margin improved to 62.3% in the third quarter of 2024, up from 60.6% in the same period last year.
• Operating expenses decreased by 25% year-over-year, indicating cost management efforts.
• Loss from operations improved by 28% year-over-year, showing progress in reducing losses.
• The installed base of instruments grew by 15% year-over-year, demonstrating continued adoption of Akoya's technology.
• The number of publications citing Akoya's technology increased by 47% year-over-year, highlighting the growing scientific validation of their products.
• Akoya introduced new product offerings at SITC, which are expected to drive future reagent revenue growth.

Negatives

• Third-quarter revenue decreased by 25% year-over-year, indicating a significant slowdown in sales.
• Year-to-date revenue decreased by 14% compared to the prior year period.
• The company has lowered its full-year 2024 revenue outlook from $96-$104 million to $80-$85 million, reflecting weaker than expected performance.
• The company experienced a loss from operations of $8.3 million for the quarter and $41 million year to date.

Risks

• The company is facing ongoing capital equipment purchase constraints in the life science tools market.
• The current economic environment is posing temporary challenges to the company's growth.
• The company's revenue outlook for 2024 has been significantly reduced, indicating potential future challenges.
• The company is evaluating strategic alternatives, which could indicate uncertainty about its future direction.

Future Outlook

Akoya expects full-year 2024 revenue to be in the range of $80 million to $85 million. The company is also evaluating strategic alternatives to enhance growth and profitability.

Management Comments

• Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market.
• We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges.
• We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and enhanced our readiness to absorb the headwinds we are facing.
• We remain confident that Akoyas technologies will continue to be the preferred platform in the spatial biology market from discovery to diagnostics, supporting a return to topline growth in 2025, and beyond, and achievement of our profitability goals.

Industry Context

The report indicates that Akoya is experiencing challenges due to broader market conditions affecting capital equipment purchases in the life science tools sector. This suggests that other companies in the same industry may also be facing similar headwinds.

Comparison to Industry Standards

• While Akoya's gross margin improved, the significant revenue decline of 25% year-over-year is concerning, especially when compared to other companies in the life science tools sector that have shown more resilience.
• Companies like Bio-Rad Laboratories and Illumina, while also facing some market pressures, have not reported such a steep decline in revenue, suggesting Akoya may be facing company-specific challenges in addition to industry-wide issues.
• The reduction in operating expenses is a positive step, but it needs to be coupled with revenue growth to achieve sustainable profitability. Other companies in the sector are also focused on cost management, but they are generally doing so while maintaining or growing revenue.
• Akoya's installed base growth of 15% is positive, but the revenue decline indicates that the company may not be effectively monetizing its installed base compared to competitors with similar growth rates.

Management Changes

Stakeholder Impact

• Shareholders will be negatively impacted by the lower revenue and reduced outlook.
• Employees may be affected by the organizational restructuring and potential strategic changes.
• Customers may experience changes in product availability or support due to the company's restructuring.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's reduced revenue and profitability.

Next Steps

• Akoya will host a conference call on November 14, 2024, to discuss the third quarter 2024 financial results.
• The company will continue to evaluate strategic alternatives to improve growth and profitability.

Key Dates

Keywords

Spatial Biology, Phenotyping, Immunotherapy, Life Science Tools, Financial Results, Revenue, Gross Margin, Operating Expenses, Loss from Operations, Akoya Biosciences